{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a structured layout to present a case study of a peer company's clinical and financial milestones.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/18",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Significant share price and valuation uplift post successful results Phase II (+£1.7b) and Phase III (+£1.6b)",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a21b-fd491349836c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.2,
        "y": 0.48
      },
      "kind": "chart",
      "text": "Market cap of $5.5bn (09-Jan-2018) driven by positive Phase II and III results",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3e3a5aa-5de0-4eda-ad08-0296443c9ab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.32
      },
      "kind": "list",
      "text": "SAGE-217 positive Phase III results in PPD (Jan 2019)\nPPD Phase III met primary and secondary endpoints (Jan-2019)\nMDD Phase II met primary endpoint (Dec 2017)\nPPD Phase II met primary endpoint (Jun 2017)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13166368-3d97-40df-8531-1eae853c2762",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.15
      },
      "kind": "list",
      "text": "Relevant assets in same indication (MDD, PPD, Bipolar Depression)\nSAGE-547 (registration phase): IV formulation being investigated for Post-Partum Depression (PPD), as well as epilepsy\nSAGE-217 (Phase III): oral drug being investigated for among others Major Depressive Disorder (MDD), PPD, and Bipolar Depression",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "266a6a53-e4ec-4c53-84a4-9912da11c775",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.2,
        "y": 0.75
      },
      "kind": "list",
      "text": "Despite positive vote FDA advisory committee on risk/benefit profile SAGE-547 (Nov-2018), potential strict requirements may limit future uptake\n72-hour infusion process to be done under 24/7 medical care\nFDA panel vague on additional data required for home infusion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97203edd-5f63-4f3f-be9d-b6579c94ba4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Market Cap: £5.5bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a21c-0011405c53bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: ClinicalTrials.gov; Comparables Analysis; SAGE website; Bloomberg Biomedtracker (2016); Endpoints News (2018); Oanda.com",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "271b3c26-27af-49ef-983b-f51b119d08a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Sage Therapeutics: Significant valuation uplift post successful Phase II (+£1.7b) and Phase III (+£1.6b) results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5f88244-1dd8-443d-8904-83908f41dde9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}